In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 101 to 110 of 366

Sort by

Type: Guidance`Remove $Type: Guidance filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530]	Technology appraisal guidance	TBC
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]	Highly specialised technology	TBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]	Technology appraisal guidance	TBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]	Technology appraisal guidance	TBC
Dupilumab for treating chronic spontaneous urticaria inadequately controlled by H1 antihistamines in children 2 to 11 years [TSID12421]	Technology appraisal guidance	TBC
Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]	Technology appraisal guidance	TBC
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]	Technology appraisal guidance	TBC
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]	Technology appraisal guidance	TBC
Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409]	Technology appraisal guidance	18 November 2026
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]	Technology appraisal guidance	TBC

Results per page

10
25
50
All